Neuraxis, Inc. Form 8-K Summary
Reporting period/event: The report was filed March 28, 2024, regarding a material agreement executed March 22, 2024. Neuraxis, Inc. is an emerging growth company headquartered in Carmel, Indiana, with common stock trading on the NYSE American under the symbol NRXS.
Material Financing Agreement
- Neuraxis and Flagstaff International, LLC amended their securities purchase agreement to increase the planned investment from $3 million to $5 million.
- The investment will be made through a convertible promissory note funded in 15 monthly installments of differing amounts.
- As of the filing date, Flagstaff had funded $400,000, with 13 monthly payments remaining.
- Upon stockholder approval and filing of a Certificate of Designation, the note will be convertible into 2,100,841 shares of Series B Convertible Preferred Stock.
- The Series B Preferred Stock is expected to be convertible into common stock and rank senior to common stock in liquidation, dissolution, and winding-up payments.
- The company has not yet sought the required stockholder approval as of the filing date.
Use of Proceeds and Financial Metrics
- Proceeds must be used solely for working capital and general corporate purposes.
- Proceeds may not be used for dividends, distributions, or payments or advances to officers, directors, or affiliates.
- The filing does not provide revenue, profit, cash-flow, margin, debt, or liquidity figures for a comparable reporting period.
Changes Versus Prior Terms
- The March 22 amendment increased the aggregate financing commitment by $2 million, from $3 million to $5 million.
- The financing structure changed from the planned direct issuance of Series B Preferred Stock to issuance of a convertible promissory note.
- Following the required corporate approvals, the note is intended to convert into Series B Preferred Stock rather than continuing as a note for the applicable funded amounts.
- A prior amendment required the company to file a resale registration statement for common stock underlying the Series B Preferred Stock within 15 business days after stockholder approval.
Outlook, Risks, and Contingencies
- Closing and conversion remain contingent on stockholder approval and the filing of the Certificate of Designation with the Delaware Secretary of State.
- The company has not yet obtained stockholder approval, and the timing and completion of the planned financing are therefore uncertain.
- The transaction will create potential dilution to existing common stockholders through conversion into preferred stock and, potentially, common stock.
- The filing does not provide formal financial guidance or broader operating outlook commentary.
Investor Verification Items
- Verify whether Neuraxis subsequently obtained stockholder approval and filed the Certificate of Designation.
- Confirm the amounts and timing of the 13 remaining monthly installments.
- Review the convertible note for interest, maturity, conversion mechanics, events of default, and other investor protections.
- Monitor the required resale registration statement and the potential share dilution from conversion.
- Assess the company’s separate financial statements for cash runway, operating losses, liquidity needs, and ability to meet the remaining funding obligations.